Loading…
GANX
Gain Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 36269B105
$1.77-4.32%Price as of Aug 29, 18:41 UTC · updated once a day, after the close
Key metrics
- Market cap
- $77.25M
- P/E
- —
- Forward P/E
- —
- P/B
- 6.8x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.48
- ROE
- -268.30%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.20
- 52-week high
- $4.34
- 52-week low
- $1.53
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -74.4% over 5Y.
today you would have $239.09▼ -76.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $3.22 | $2.16 | $3.27 | $3.13 | $5.43 | |
| P/S | 391.1x | — | — | 959.7x | 265.5x | 391.1x |
| P/B | 4.2x | 7.3x | 8.2x | 4.2x | 2.0x | 1.9x |
| EPS | -$0.61 | -$0.89 | -$1.71 | -$1.48 | -$1.37 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CINGCingulate Inc. | $5.33 | — | 3.2x | — | -198.74% | $77.44M |
| APLMApollomics Inc. | $26.60 | — | — | — | -1305.37% | $77.04M |
| OSTXOS Therapies Inc | $1.64 | — | — | — | — | $76.21M |
| TELOTelomir Pharmaceuticals, Inc. | $1.14 |
About the company
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
- 20
- Bethesda, United States
Company description provided by Yahoo Finance.